Shoot­ing for $100M IPO, Schrödinger takes the wraps off its five in­ter­nal drugs and dis­clos­es deal de­tails

Just be­fore last year’s JP Mor­gan con­fab kicked off, Schrödinger un­veiled its first ven­ture round fea­tur­ing in­sti­tu­tion­al in­vestors be­fore lat­er clos­ing the Se­ries E at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.